Research graph
References from Advances and disparities in survival of childhood and adolescent cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2019 · External reference
Deaths: leading Causes for 2019
2021 · External reference
Cancer statistics for adolescents and young adults, 2020
10.3322/caac.21637 · 2020 · External reference
Cancer Statistics, 2026
10.3322/caac.70043 · 2026 · External reference
Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study
10.1200/jco.2008.21.1425 · 2009 · External reference
Childhood and Adolescent Cancer Statistics, 2014
10.3322/caac.21219 · 2014 · External reference
Recent progress in the treatment of cancer in children
10.3322/caac.21665 · 2021 · External reference
Poverty and targeted immunotherapy: survival in children’s oncology group clinical trials for high-risk neuroblastoma
10.1093/jnci/djaa107 · 2021 · External reference
Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma
10.1002/cncr.30089 · 2016 · External reference
10.15620/cdc:134499
10.15620/cdc:134499 · 2023 · External reference
Persistence of racial and ethnic disparities in risk and survival for patients with neuroblastoma over two decades
10.1016/j.ejcped.2023.100022 · 2023 · External reference
Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study
10.1200/jco.2010.29.6103 · 2011 · External reference
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children’s Oncology Group report
10.1093/jnci/djae103 · 2024 · External reference
Racial and ethnic survival disparities among children with high-risk neuroblastoma: a children’s oncology group report
10.1001/jamanetworkopen.2024.58531 · 2025 · External reference
Unresolved reference
2024 · External reference
International classification of childhood cancer, third edition
10.1002/cncr.20910 · 2005 · External reference
Classification schemes for tumors diagnosed in adolescents and young adults
10.1002/cncr.21773 · 2006 · External reference
CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018
10.1093/neuonc/noac161 · 2022 · External reference
Permutation tests for joinpoint regression with applications to cancer rates
10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co · 2000 · External reference
Unresolved reference
2025 · External reference
Cancer treatment and survivorship statistics, 2019
10.3322/caac.21565 · 2019 · External reference
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
10.1016/s1470-2045(19)30031-2 · 2019 · External reference
Racial and ethnic survival disparities in pediatric oncology over time: an analysis of the SEER registry
10.1016/j.jpedsurg.2024.161953 · 2025 · External reference
Inequities in pediatric cancer: unveiling the impact of social determinants of health on survival
10.1002/pbc.31742 · 2025 · External reference
Excess risk of chronic health conditions in Hispanic survivors of adolescent and young adult cancers
10.1007/s11764-023-01342-z · 2024 · External reference
Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate
10.1002/cncr.34646 · 2023 · External reference
Declining childhood and adolescent cancer mortality
10.1002/cncr.28748 · 2014 · External reference
Children’s oncology group blueprint for research: acute lymphoblastic leukemia
10.1002/pbc.30585 · 2023 · External reference
Advancing diagnostics and therapy to reach universal cure in childhood ALL
10.1200/jco.23.01286 · 2023 · External reference
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia
10.1182/blood.2019003191 · 2020 · External reference
Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia
10.1200/jco.2017.74.0449 · 2018 · External reference
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia
10.1182/bloodadvances.2019000163 · 2020 · External reference
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia
10.1038/s41375-018-0307-6 · 2019 · External reference
Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae
10.1016/j.currproblcancer.2021.100777 · 2021 · External reference
Conventional and advanced MRI features of pediatric intracranial tumors: posterior fossa and suprasellar tumors
10.2214/ajr.12.9725 · 2013 · External reference
Conventional and advanced MRI features of pediatric intracranial tumors: supratentorial tumors
10.2214/ajr.12.9724 · 2013 · External reference
Children’s oncology group AALL1331: phase III trial of Blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse
10.1200/jco.22.02200 · 2023 · External reference
Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children
10.1056/nejmoa2411680 · 2025 · External reference
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
10.1186/s12885-019-6442-2 · 2019 · External reference
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
10.1056/nejmoa2303815 · 2023 · External reference
Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children
10.1056/nejmoa1915315 · 2020 · External reference
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma
10.1111/bjh.16461 · 2020 · External reference
Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations
10.3390/cancers13092075 · 2021 · External reference
Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma
10.1111/bjh.15753 · 2019 · External reference
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children’s Oncology Group cohort trials
10.1016/s2352-3026(22)00371-4 · 2023 · External reference
Racial and ethnic disparities in survival of children with brain and central nervous tumors in the United States
10.1002/pbc.28738 · 2021 · External reference
Minority children experience a higher risk of death from many central nervous system tumor types even after accounting for treatment received: a National Cancer Database analysis
10.1002/cncr.34121 · 2022 · External reference
Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015
10.1111/bjh.16491 · 2020 · External reference
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials
10.1016/s2352-3026(21)00349-5 · 2022 · External reference
Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study
10.1002/pbc.23090 · 2011 · External reference
Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. recommendations from the EuroNet pediatric Hodgkin lymphoma group
10.1097/hs9.0000000000000329 · 2020 · External reference
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425
10.1182/blood-2008-10-184143 · 2009 · External reference
Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma
10.1056/nejmoa2206660 · 2022 · External reference
Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma
10.1056/nejmoa2405888 · 2024 · External reference
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group
10.1200/jco.2005.01.2799 · 2005 · External reference
Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a children’s oncology group AREN0532 and AREN0533 study report
10.1200/jco.18.01972 · 2019 · External reference
Anaplasia in Wilms tumor: a critical review
10.1002/pbc.31000 · 2024 · External reference
Treatment with nephrectomy only for small, stage I/favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group
10.1200/jco.2001.19.17.3719 · 2001 · External reference
Clinical outcome and biological predictors of relapse after nephrectomy only for very low-risk Wilms tumor: a report from children’s oncology group AREN0532
10.1097/sla.0000000000001716 · 2017 · External reference
Surgical management of prepubertal testicular tumors: a 30-year study in our institution
10.1111/iju.15168 · 2023 · External reference
Management trends in pediatric nonseminomatous germ cell tumors
10.1016/j.urology.2021.02.024 · 2021 · External reference
Impact of surgical timing (primary, delayed, or second look) on surgical morbidity and outcomes in malignant germ cell tumor of the ovary in children
10.1016/j.jpedsurg.2024.02.017 · 2024 · External reference
Ovarian-sparing surgery for ovarian tumors in children: a systematic review and meta-analysis
10.1016/j.ejso.2023.04.022 · 2023 · External reference
Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: a systematic review
10.1016/j.jpedsurg.2018.12.021 · 2019 · External reference
Fertility preservation and restoration options for pre-pubertal male cancer patients: current approaches
10.3389/fendo.2022.877537 · 2022 · External reference
Integration of pediatric Hodgkin lymphoma treatment and late effects guidelines: seeing the forest beyond the trees
10.6004/jnccn.2021.7042 · 2021 · External reference
Closing the survivorship gap in children and adolescents with Hodgkin lymphoma
10.1111/bjh.16197 · 2019 · External reference
Late health outcomes among survivors of Wilms tumor diagnosed over three decades: a report from the childhood cancer survivor study
10.1200/jco.22.02111 · 2023 · External reference
Treatment and survival of malignant extracranial germ cell tumours in the paediatric population: a systematic review and meta-analysis
10.3390/cancers13143561 · 2021 · External reference
Diagnosis and treatment of early-stage testicular cancer: AUA Guideline Amendment 2023
10.1097/ju.0000000000003694 · 2024 · External reference
Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: a comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
10.1002/pbc.30426 · 2023 · External reference
A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
10.1016/j.ejca.2019.03.001 · 2019 · External reference
Race and ethnic group enrollment and outcomes for Wilms tumor: analysis of the current era children’s oncology group study, AREN03B2
10.1097/xcs.0000000000000999 · 2024 · External reference
Incidence and survival of children and adolescents with Wilms tumor, United States, 2001-2020
10.1002/cam4.70598 · 2025 · External reference
Survival differences by race/ethnicity among children and adolescents diagnosed with germ cell tumors
10.1002/ijc.32569 · 2020 · External reference
Impact of race, ethnicity, and socioeconomic status over time on the long-term survival of adolescent and young adult Hodgkin lymphoma survivors
10.1158/1055-9965.epi-21-0103 · 2021 · External reference
Racial and ethnic disparities in the pediatric Hodgkin lymphoma population
10.1002/pbc.25802 · 2016 · External reference
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98
10.1200/jco.2009.25.6321 · 2010 · External reference
Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12
10.1200/jco.2009.24.8997 · 2010 · External reference
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
10.1200/jco.2008.17.9184 · 2009 · External reference
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project
10.1002/pbc.27819 · 2019 · External reference
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report
10.1002/pbc.24532 · 2013 · External reference
Pharmacogenomics, race, and treatment outcome in pediatric acute myeloid leukemia
10.1001/jamanetworkopen.2024.11726 · 2024 · External reference
Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia
10.1182/bloodadvances.2021004735 · 2021 · External reference
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study
10.1097/sla.0b013e31826cbbbd · 2012 · External reference
Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the children’s oncology group study ANBL0531
10.1200/jco.19.00919 · 2019 · External reference
Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial
10.1001/jama.2019.11642 · 2019 · External reference
A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019
10.1002/pbc.30732 · 2024 · External reference
Trends in conditional survival and predictors of late death in neuroblastoma
10.1002/pbc.28329 · 2020 · External reference
Surgical advances in osteosarcoma
10.3390/cancers13030388 · 2021 · External reference
Children’s oncology group’s 2023 blueprint for research: neuroblastoma
10.1002/pbc.30572 · 2023 · External reference
Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children’s Oncology Group
10.1016/s2352-4642(25)00241-x · 2025 · External reference
Children’s oncology group’s 2023 blueprint for research: soft tissue sarcomas
10.1002/pbc.30556 · 2023 · External reference
Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients
10.1016/j.canep.2017.08.015 · 2017 · External reference
Cancer Statistics, 2025
10.3322/caac.21871 · 2025 · External reference
Trends in cancer incidence in US Adolescents and Young Adults, 1973-2015
10.1001/jamanetworkopen.2020.27738 · 2020 · External reference
A guide to large data sets for population-based cancer research: strengths, limitations, and pitfalls
10.1002/cncr.35535 · 2024 · External reference
Research challenges in adolescent and young adult cancer survivor research
10.1002/cncr.26058 · 2011 · External reference
Conditional survival in pediatric malignancies: analysis of data from the childhood cancer survivor study and the surveillance, epidemiology, and end results program
10.1002/cncr.29170 · 2015 · External reference
The childhood cancer survivor study: a national cancer institute–supported resource for outcome and intervention research
10.1200/jco.2009.22.3339 · 2009 · External reference
Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research
10.1016/s0895-4356(97)00099-1 · 1997 · External reference
How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?
10.1007/s10552-004-1324-5 · 2004 · External reference
Racial/ethnic disparities in childhood cancer survival in the United States
10.1158/1055-9965.epi-21-0117 · 2021 · External reference
Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival?
10.1002/cncr.31560 · 2018 · External reference
Associations between race/ethnicity and US childhood and adolescent cancer survival by treatment amenability
10.1001/jamapediatrics.2019.6074 · 2020 · External reference
